Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
Drug-durg Interaction of Leritrelvir(RAY1216) With Midazolam, Omeprazole, Rosuvastatin, Verapamil, and Rifampin
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT06031454
- Locations
- 🇨🇳
the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT05932277
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT05891119
- Locations
- 🇺🇸
Direct Helpers Research Center (DHRC), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States
🇺🇸DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT05852769
- Locations
- 🇺🇸
ICON plc, Millcreek, Utah, United States
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT05741385
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Aya Mohamed Sadek Elsaid
- Target Recruit Count
- 46
- Registration Number
- NCT05680870
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT05635110
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05599828
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05581992
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.